The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC. Methods: We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups: a short SER group (< 60 days) and a long SER (> 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy. Results: Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed. Conclusions: Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.

Original languageEnglish
Pages (from-to)449-455
Number of pages7
JournalKorean Journal of Internal Medicine
Volume28
Issue number4
DOIs
Publication statusPublished - 2013 Jul 1

Fingerprint

Small Cell Lung Carcinoma
Radiotherapy
Drug Therapy
irinotecan
Chemoradiotherapy
Appointments and Schedules
Thorax
Survival Rate
Radiation
Therapeutics

Keywords

  • Chemoradiotherapy
  • Limited-stage
  • Small cell lung carcinoma
  • Start of any treatment until the end of radiotherapy

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{63bbe2f2cf8e41faa1c52fc0c17823e7,
title = "The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer",
abstract = "Background/Aims: Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC. Methods: We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups: a short SER group (< 60 days) and a long SER (> 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy. Results: Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed. Conclusions: Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.",
keywords = "Chemoradiotherapy, Limited-stage, Small cell lung carcinoma, Start of any treatment until the end of radiotherapy",
author = "Lee, {Kyoung Ju} and Lee, {Eun Joo} and Hur, {Gyu Young} and Lee, {Sang Yeub} and Kim, {Je Hyeong} and Chol Shin and Shim, {Jae Jeong} and In, {Kwang Ho} and Kang, {Kyung Ho} and Yoo, {Se Hwa} and Lee, {Sung Yong}",
year = "2013",
month = "7",
day = "1",
doi = "10.3904/kjim.2013.28.4.449",
language = "English",
volume = "28",
pages = "449--455",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "4",

}

TY - JOUR

T1 - The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer

AU - Lee, Kyoung Ju

AU - Lee, Eun Joo

AU - Hur, Gyu Young

AU - Lee, Sang Yeub

AU - Kim, Je Hyeong

AU - Shin, Chol

AU - Shim, Jae Jeong

AU - In, Kwang Ho

AU - Kang, Kyung Ho

AU - Yoo, Se Hwa

AU - Lee, Sung Yong

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Background/Aims: Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC. Methods: We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups: a short SER group (< 60 days) and a long SER (> 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy. Results: Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed. Conclusions: Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.

AB - Background/Aims: Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC. Methods: We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups: a short SER group (< 60 days) and a long SER (> 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy. Results: Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed. Conclusions: Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.

KW - Chemoradiotherapy

KW - Limited-stage

KW - Small cell lung carcinoma

KW - Start of any treatment until the end of radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84880422687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880422687&partnerID=8YFLogxK

U2 - 10.3904/kjim.2013.28.4.449

DO - 10.3904/kjim.2013.28.4.449

M3 - Article

C2 - 23864803

AN - SCOPUS:84880422687

VL - 28

SP - 449

EP - 455

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 4

ER -